Advanced cutaneous melanoma and Advanced mucosal melanoma research hub

A Phase 2, Open-Label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6

This study, called ARTISTRY-6, is looking at new ways to treat advanced skin and mucosal melanoma. It's testing a new medicine called Nemvaleukin Alfa, both on its own and with another drug, Pembrolizumab, to see how well they work and if they help shrink the cancer.